Clinical Trial Update: Efficacy and Safety of Efsubaglutide Alfa Injection 3 Mg Q2W in T2D Patients [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating Efsubaglutide Alfa Injection 3 mg every two weeks in type 2 diabetes mellitus has not yet started recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Efsubaglutide Alfa Injection (Efsubaglutide Alfa)

Snippet

Sponsor: Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. | Conditions: Type 2 Diabetes | Phase 3 | Status: NOT_YET_RECRUITING